{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T20:01:37Z","timestamp":1792612897310,"version":"4.5.0"},"reference-count":77,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T00:00:00Z","timestamp":1758931200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81873444"],"award-info":[{"award-number":["81873444"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82,070,213"],"award-info":[{"award-number":["82,070,213"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82,370,196"],"award-info":[{"award-number":["82,370,196"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Translational Oncology"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.tranon.2025.102555","type":"journal-article","created":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T03:17:08Z","timestamp":1759547828000},"page":"102555","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["CD70-targeted CAR-T\/NK therapy: Rationale, advances, and future directions"],"prefix":"10.1016","volume":"62","author":[{"given":"Sijia","family":"Yan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojian","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tranon.2025.102555_bib0001","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pharmthera.2015.07.007","article-title":"CD70: an emerging target in cancer immunotherapy","volume":"155","author":"Jacobs","year":"2015","journal-title":"Pharmacol. Ther."},{"issue":"1","key":"10.1016\/j.tranon.2025.102555_bib0002","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s13046-021-02215-y","article-title":"The CD70-CD27 axis in oncology: the new kids on the block","volume":"41","author":"Flieswasser","year":"2022","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"5","key":"10.1016\/j.tranon.2025.102555_bib0003","doi-asserted-by":"crossref","first-page":"2282","DOI":"10.4049\/jimmunol.1300868","article-title":"CD70 is downregulated by interaction with CD27","volume":"191","author":"Kuka","year":"2013","journal-title":"J. Immunol."},{"key":"10.1016\/j.tranon.2025.102555_bib0004","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2023.103137","article-title":"Associations between CD70 methylation of T cell DNA and age in adults with systemic lupus erythematosus and population controls: the Michigan Lupus Epidemiology & Surveillance (MILES) program","volume":"142","author":"Somers","year":"2024","journal-title":"J. Autoimmun."},{"issue":"9","key":"10.1016\/j.tranon.2025.102555_bib0005","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1158\/1078-0432.CCR-16-1421","article-title":"Preclinical evaluation of chimeric antigen receptors targeting CD70-expressing cancers","volume":"23","author":"Wang","year":"2017","journal-title":"Clin. Cancer Res."},{"issue":"16","key":"10.1016\/j.tranon.2025.102555_bib0006","doi-asserted-by":"crossref","first-page":"4304","DOI":"10.1182\/blood-2010-04-278218","article-title":"T cells redirected against CD70 for the immunotherapy of CD70-positive malignancies","volume":"117","author":"Shaffer","year":"2011","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.tranon.2025.102555_bib0007","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2024.2338984","article-title":"Global research trends in CAR-T cell therapy for solid tumors: a comprehensive visualization and bibliometric study (2012\u20132023)","volume":"20","author":"Miao","year":"2024","journal-title":"Hum. Vaccin. Immunother."},{"issue":"12","key":"10.1016\/j.tranon.2025.102555_bib0008","doi-asserted-by":"crossref","first-page":"E930","DOI":"10.1016\/S2352-3026(22)00291-5","article-title":"CAR T-cell therapies in China: rapid evolution and a bright future","volume":"9","author":"Hu","year":"2022","journal-title":"Lancet Haematol."},{"issue":"6","key":"10.1016\/j.tranon.2025.102555_bib0009","first-page":"2183","article-title":"CAR T cell therapy: a new era for cancer treatment","volume":"42","author":"Mohanty","year":"2019","journal-title":"Oncol. Rep."},{"issue":"11","key":"10.1016\/j.tranon.2025.102555_bib0010","article-title":"CAR-T cell therapy for hematological malignancies: history, status and promise","volume":"9","author":"Wang","year":"2023","journal-title":"Heliyon"},{"issue":"3","key":"10.1016\/j.tranon.2025.102555_bib0011","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1182\/blood-2007-09-077438","article-title":"Human natural killer cells","volume":"112","author":"Caligiuri","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.tranon.2025.102555_bib0012","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2020.102975","article-title":"CAR-NK cells: a promising cellular immunotherapy for cancer","volume":"59","author":"Xie","year":"2020","journal-title":"eBioMedicine"},{"issue":"12","key":"10.1016\/j.tranon.2025.102555_bib0013","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1038\/s41590-023-01659-y","article-title":"Forks in the road for CAR T and CAR NK cell cancer therapies","volume":"24","author":"Dagher","year":"2023","journal-title":"Nat. Immunol."},{"issue":"1","key":"10.1016\/j.tranon.2025.102555_bib0014","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1186\/s13046-022-02327-z","article-title":"CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy","volume":"41","author":"Pan","year":"2022","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.tranon.2025.102555_bib0015","doi-asserted-by":"crossref","DOI":"10.1080\/16078454.2024.2310960","article-title":"Clinical features and outcomes of patients with acute myeloid leukemia: the single-center experience of 668 patients in China","volume":"29","author":"Ding","year":"2024","journal-title":"Hematology"},{"issue":"2","key":"10.1016\/j.tranon.2025.102555_bib0016","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1084\/jem.20152008","article-title":"CD70\/CD27 signaling promotes blast stemness and is a viable therapeutic target in acute myeloid leukemia","volume":"214","author":"Riether","year":"2017","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.tranon.2025.102555_bib0017","article-title":"Preclinical evaluation of CD70-specific CAR T cells targeting acute myeloid leukemia","volume":"14","author":"Wu","year":"2023","journal-title":"Front. Immunol."},{"issue":"4","key":"10.1016\/j.tranon.2025.102555_bib0018","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1182\/blood.2020008221","article-title":"CD70-specific CAR T cells have potent activity against acute myeloid leukemia without HSC toxicity","volume":"138","author":"Sauer","year":"2021","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.tranon.2025.102555_bib0019","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.ccell.2022.04.001","article-title":"Non-cleavable hinge enhances avidity and expansion of CAR-T cells for acute myeloid leukemia","volume":"40","author":"Leick","year":"2022","journal-title":"Cancer Cell"},{"issue":"7","key":"10.1016\/j.tranon.2025.102555_bib0020","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1007\/s00262-023-03422-6","article-title":"Preclinical development and evaluation of nanobody-based CD70-specific CAR T cells for the treatment of acute myeloid leukemia","volume":"72","author":"Cheng","year":"2023","journal-title":"Cancer Immunol. Immunother."},{"issue":"9","key":"10.1016\/j.tranon.2025.102555_bib0021","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1038\/s41591-020-0910-8","article-title":"Targeting CD70 with cusatuzumab eliminates acute myeloid leukemia stem cells in patients treated with hypomethylating agents","volume":"26","author":"Riether","year":"2020","journal-title":"Nat. Med."},{"issue":"5","key":"10.1016\/j.tranon.2025.102555_bib0022","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1007\/s00428-024-03741-8","article-title":"Increased expression of CD70 in relapsed acute myeloid leukemia after hypomethylating agents","volume":"485","author":"Marques-Piubelli","year":"2024","journal-title":"Virchows Arch."},{"issue":"Supplement 1","key":"10.1016\/j.tranon.2025.102555_bib0023","doi-asserted-by":"crossref","first-page":"7396","DOI":"10.1182\/blood-2022-170503","article-title":"LigandCD70.CAR as a platform for dual-targeting CAR T cells for acute myeloid leukemia","volume":"140","author":"Scherer","year":"2022","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.tranon.2025.102555_bib0024","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.3390\/cancers11101611","article-title":"Screening a broad range of solid and haematological tumour types for CD70 expression using a uniform IHC methodology as potential patient stratification method","volume":"11","author":"Flieswasser","year":"2019","journal-title":"Cancers"},{"issue":"Supplement 1","key":"10.1016\/j.tranon.2025.102555_bib0025","doi-asserted-by":"crossref","first-page":"6839","DOI":"10.1182\/blood-2023-188533","article-title":"Evaluation of CD70 chimeric antigen receptor T (CAR-T) cells as a potential treatment for non-Hodgkin\u2019s lymphoma: a preclinical study","volume":"142","author":"Jiang","year":"2023","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.tranon.2025.102555_bib0026","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1002\/cac2.12201","article-title":"CD70-targeting CAR-T cells have potential activity against CD19-negative B-cell lymphoma","volume":"41","author":"Deng","year":"2021","journal-title":"Cancer Commun."},{"key":"10.1016\/j.tranon.2025.102555_bib0027","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.3389\/fonc.2019.01350","article-title":"CD19 and CD70 dual-target chimeric antigen receptor T-cell therapy for relapsed and refractory primary CNS diffuse large B-cell lymphoma","volume":"9","author":"Tu","year":"2019","journal-title":"Front. Oncol."},{"issue":"11","key":"10.1016\/j.tranon.2025.102555_bib0028","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1182\/bloodadvances.2023012202","article-title":"CD70-specific CAR-NK cells expressing IL-15 for CD19-negative B-cell malignancy","volume":"8","author":"Guo","year":"2024","journal-title":"Blood Adv."},{"issue":"Supplement 1","key":"10.1016\/j.tranon.2025.102555_bib0029","doi-asserted-by":"crossref","first-page":"4493","DOI":"10.1182\/blood-2021-146990","article-title":"CD70 expression in mature T-cell lymphomas","volume":"138","author":"Marques-Piubelli","year":"2021","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.tranon.2025.102555_bib0030","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1111\/his.14670","article-title":"CD70 is a potential target biomarker in peripheral T-cell lymphomas","volume":"81","author":"Marques-Piubelli","year":"2022","journal-title":"Histopathology"},{"key":"10.1016\/j.tranon.2025.102555_bib0031","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1016\/S0959-8049(22)00591-3","article-title":"The COBALT-LYM study of CTX130: a phase 1 dose escalation study of CD70-targeted allogeneic CRISPR-Cas9\u2013engineered CAR T cells in relapsed\/refractory T-cell malignancies","volume":"173","author":"Zain","year":"2022","journal-title":"Eur. J. Cancer"},{"issue":"16_Supplement","key":"10.1016\/j.tranon.2025.102555_bib0032","doi-asserted-by":"crossref","first-page":"6595","DOI":"10.1158\/1538-7445.AM2020-6595","article-title":"Abstract 6595: targeting T-cell lymphomas with CRISPR\/Cas9-generated anti-CD70 allogeneic CAR-T cells","volume":"80","author":"Karnik","year":"2020","journal-title":"Cancer Res."},{"key":"10.1016\/j.tranon.2025.102555_bib0033","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/S1470-2045(24)00508-4","article-title":"Safety and activity of CTX130, a CD70-targeted allogeneic CRISPR-Cas9-engineered CAR T-cell therapy, in patients with relapsed or refractory T-cell malignancies (COBALT-LYM): a single-arm, open-label, phase 1, dose-escalation study","volume":"26","author":"Iyer","year":"2025","journal-title":"Lancet Oncol."},{"issue":"Supplement 1","key":"10.1016\/j.tranon.2025.102555_bib0034","doi-asserted-by":"crossref","first-page":"4811","DOI":"10.1182\/blood-2023-184864","article-title":"Targeting T-cell lymphoma using CD70-directed cord blood-derived CAR-NK cells","volume":"142","author":"Rafei","year":"2023","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.tranon.2025.102555_bib0035","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1053\/j.seminoncol.2016.11.004","article-title":"Multiple myeloma epidemiology and survival: a unique malignancy","volume":"43","author":"Kazandjian","year":"2016","journal-title":"Semin. Oncol."},{"issue":"23","key":"10.1016\/j.tranon.2025.102555_bib0036","doi-asserted-by":"crossref","first-page":"7763","DOI":"10.1158\/1078-0432.CCR-08-0493","article-title":"Preclinical characterization of SGN-70, a humanized antibody directed against CD70","volume":"14","author":"McEeachern","year":"2008","journal-title":"Clin. Cancer Res."},{"issue":"Supplement 1","key":"10.1016\/j.tranon.2025.102555_bib0037","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1182\/blood-2023-182578","article-title":"Discovery and development of CD70 As a cellular therapy target in high risk multiple myeloma","volume":"142","author":"Kasap","year":"2023","journal-title":"Blood"},{"issue":"15","key":"10.1016\/j.tranon.2025.102555_bib0038","doi-asserted-by":"crossref","first-page":"6780","DOI":"10.1002\/cam4.2552","article-title":"Racial\/ethnic disparities in renal cell carcinoma: increased risk of early-onset and variation in histologic subtypes","volume":"8","author":"Batai","year":"2019","journal-title":"Cancer Med."},{"issue":"2","key":"10.1016\/j.tranon.2025.102555_bib0039","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.clgc.2023.12.003","article-title":"CD70 is consistently expressed in primary and metastatic clear cell renal cell carcinoma","volume":"22","author":"Huang","year":"2024","journal-title":"Clin. Genitourin. Cancer"},{"issue":"14","key":"10.1016\/j.tranon.2025.102555_bib0040","doi-asserted-by":"crossref","first-page":"2610","DOI":"10.1158\/0008-5472.CAN-21-2931","article-title":"Preclinical development and evaluation of allogeneic CAR T cells targeting CD70 for the treatment of renal cell carcinoma","volume":"82","author":"Panowski","year":"2022","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.tranon.2025.102555_bib0041","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1186\/s12967-024-05101-1","article-title":"The development of chimeric antigen receptor T-cells against CD70 for renal cell carcinoma treatment","volume":"22","author":"Xiong","year":"2024","journal-title":"J. Transl. Med."},{"issue":"7","key":"10.1016\/j.tranon.2025.102555_bib0042","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1158\/2159-8290.CD-24-0102","article-title":"CD70-targeted allogeneic CAR T-cell therapy for advanced clear cell renal cell carcinoma","volume":"14","author":"Pal","year":"2024","journal-title":"Cancer Discov."},{"issue":"Supplement 1","key":"10.1016\/j.tranon.2025.102555_bib0043","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1182\/blood-2020-142161","article-title":"Investigation of ALLO-316: a fratricide-resistant allogeneic CAR T targeting CD70 as a potential therapy for the treatment of AML","volume":"136","author":"Srinivasan","year":"2020","journal-title":"Blood"},{"issue":"8_Supplement","key":"10.1016\/j.tranon.2025.102555_bib0044","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2023-CT011","article-title":"Abstract CT011: a phase 1 multicenter study (TRAVERSE) evaluating the safety and efficacy of ALLO-316 following conditioning regimen in patients with advanced or metastatic clear cell renal cell carcinoma (ccRCC)","volume":"83","author":"Srour","year":"2023","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.tranon.2025.102555_bib0045","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1186\/s13045-021-01168-1","article-title":"Targeting the DNA damage response enhances CD70 CAR-T cell therapy for renal carcinoma by activating the cGAS-STING pathway","volume":"14","author":"Ji","year":"2021","journal-title":"J. Hematol. Oncol."},{"issue":"1","key":"10.1016\/j.tranon.2025.102555_bib0046","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1093\/neuonc\/nox116","article-title":"CD70, a novel target of CAR T-cell therapy for gliomas","volume":"20","author":"Jin","year":"2018","journal-title":"Neuro Oncol."},{"issue":"2","key":"10.1016\/j.tranon.2025.102555_bib0047","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s11060-024-04656-9","article-title":"Revisiting prognostic factors of gliomatosis cerebri in adult-type diffuse gliomas","volume":"168","author":"Shin","year":"2024","journal-title":"J. Neurooncol."},{"issue":"1","key":"10.1016\/j.tranon.2025.102555_bib0048","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003289","article-title":"CD70 as an actionable immunotherapeutic target in recurrent glioblastoma and its microenvironment","volume":"10","author":"Seyfrid","year":"2022","journal-title":"J. Immunother. Cancer"},{"issue":"9","key":"10.1016\/j.tranon.2025.102555_bib0049","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/nrd4663","article-title":"Oncolytic viruses: a new class of immunotherapy drugs","volume":"14","author":"Kaufman","year":"2015","journal-title":"Nat. Rev. Drug Discov."},{"issue":"10","key":"10.1016\/j.tranon.2025.102555_bib0050","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1007\/s00262-022-03172-x","article-title":"Enhancement of CD70-specific CAR T treatment by IFN-\u03b3 released from oHSV-1-infected glioblastoma","volume":"71","author":"Zhu","year":"2022","journal-title":"Cancer Immunol. Immunother."},{"issue":"6","key":"10.1016\/j.tranon.2025.102555_bib0051","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1159\/000446569","article-title":"CD70 expression and its correlation with clinicopathological variables in squamous cell carcinoma of the head and neck","volume":"83","author":"De Meulenaere","year":"2016","journal-title":"Pathobiology"},{"key":"10.1016\/j.tranon.2025.102555_bib0052","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.oraloncology.2018.01.024","article-title":"CD70 as a target for chimeric antigen receptor T cells in head and neck squamous cell carcinoma","volume":"78","author":"Park","year":"2018","journal-title":"Oral Oncol."},{"issue":"2","key":"10.1016\/j.tranon.2025.102555_bib0053","doi-asserted-by":"crossref","first-page":"S167","DOI":"10.1016\/j.ijrobp.2023.06.267","article-title":"Irradiated tumor cell-derived exosomes modulate macrophage polarization via SHP-2\u2013mediated metabolic reprogramming","volume":"117","author":"Liu","year":"2023","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"6","key":"10.1016\/j.tranon.2025.102555_bib0054","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1093\/oncolo\/oyae022","article-title":"Clinical value of timely targeted therapy for patients with advanced non-small cell lung cancer with actionable driver oncogenes","volume":"29","author":"Stricker","year":"2024","journal-title":"Oncologist"},{"issue":"15","key":"10.1016\/j.tranon.2025.102555_bib0055","doi-asserted-by":"crossref","first-page":"13462","DOI":"10.18632\/oncotarget.3880","article-title":"Unlocking the potential of CD70 as a novel immunotherapeutic target for non-small cell lung cancer","volume":"6","author":"Jacobs","year":"2015","journal-title":"Oncotarget"},{"issue":"2","key":"10.1016\/j.tranon.2025.102555_bib0056","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.ccell.2023.01.007","article-title":"CD70 is a therapeutic target upregulated in EMT-associated EGFR tyrosine kinase inhibitor resistance","volume":"41","author":"Nilsson","year":"2023","journal-title":"Cancer Cell"},{"issue":"7","key":"10.1016\/j.tranon.2025.102555_bib0057","article-title":"CD70-targeting CAR-T and CAR-NK cells demonstrate potent activity against NSCLC drug-tolerant persister cells","volume":"83","author":"Yang","year":"2023","journal-title":"Cancer Res."},{"key":"10.1016\/j.tranon.2025.102555_bib0058","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1007\/s10555-024-10186-7","article-title":"Cancer-associated fibroblasts: a versatile mediator in tumor progression, metastasis, and targeted therapy","volume":"43","author":"Guo","year":"2024","journal-title":"Cancer Metastasis Rev."},{"key":"10.1016\/j.tranon.2025.102555_bib0059","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.3390\/ijms25052537","article-title":"Simultaneous expression of CD70 and POSTN in cancer-associated fibroblasts predicts worse survival of colorectal cancer patients","volume":"25","author":"Komura","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.tranon.2025.102555_bib0060","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.pan.2021.01.013","article-title":"Clinical relevance of CD70 expression in resected pancreatic cancer: prognostic value and therapeutic potential","volume":"21","author":"Nakamura","year":"2021","journal-title":"Pancreatology"},{"key":"10.1016\/j.tranon.2025.102555_bib0061","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s13045-024-01525-w","article-title":"IL-15-secreting CAR natural killer cells directed toward the pan-cancer target CD70 eliminate both cancer cells and cancer-associated fibroblasts","volume":"17","author":"Van den Eynde","year":"2024","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.tranon.2025.102555_bib0062","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s12935-015-0181-5","article-title":"Expression of the immune regulation antigen CD70 in osteosarcoma","volume":"15","author":"Pahl","year":"2015","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.tranon.2025.102555_bib0063","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.4049\/jimmunol.2200591","article-title":"Overview of CD70 as a potential therapeutic target for osteosarcoma","volume":"211","author":"Rav","year":"2023","journal-title":"J. Immunol."},{"key":"10.1016\/j.tranon.2025.102555_bib0064","article-title":"Targeting CD70 using CAR NK cells to enhance NK cells cytolytic effect against osteosarcoma","volume":"210","author":"Simon Rav","year":"2023","journal-title":"J. Immunol."},{"key":"10.1016\/j.tranon.2025.102555_bib0065","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.omto.2019.07.002","article-title":"B7-H3 as a novel CAR-T therapeutic target for glioblastoma","volume":"14","author":"Tang","year":"2019","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.tranon.2025.102555_bib0066","doi-asserted-by":"crossref","first-page":"7622","DOI":"10.7150\/thno.43991","article-title":"Tandem CAR-T cells targeting CD70 and B7-H3 exhibit potent preclinical activity against multiple solid tumors","volume":"10","author":"Yang","year":"2020","journal-title":"Theranostics"},{"key":"10.1016\/j.tranon.2025.102555_bib0067","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1182\/blood-2016-12-756585","article-title":"CD70 reverse signaling enhances NK cell function and immunosurveillance in CD27-expressing B-cell malignancies","volume":"130","author":"Al Sayed","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.tranon.2025.102555_bib0068","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.1007\/s00262-023-03475-7","article-title":"Revealing the impact of CD70 expression on the manufacture and functions of CAR-70 T-cells based on single-cell transcriptomics","volume":"72","author":"Cheng","year":"2023","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.tranon.2025.102555_bib0069","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1182\/blood-2021-148649","article-title":"Engineering CD70-directed CAR-NK cells for the treatment of hematological and solid malignancies","volume":"138","author":"Choi","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.tranon.2025.102555_bib0070","doi-asserted-by":"crossref","first-page":"2898","DOI":"10.1158\/1538-7445.AM2023-2898","article-title":"CAT-248, an allogeneic CD70-directed CAR-NK cell therapy effectively controls CD70-positive tumor xenografts","volume":"83","author":"Hamza","year":"2023","journal-title":"Cancer Res."},{"key":"10.1016\/j.tranon.2025.102555_bib0071","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2022-160106","article-title":"Developing CD70-targeted CAR-T cells for the treatment of hematological and solid malignancies","volume":"140","author":"Lu","year":"2022","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.tranon.2025.102555_bib0072","doi-asserted-by":"crossref","first-page":"2551","DOI":"10.1158\/1538-7445.AM2018-2551","article-title":"Allogeneic CRISPR-engineered anti-CD70 CAR T cells demonstrate potent preclinical activity against solid and hematological cancer cells","volume":"78","author":"Padalia","year":"2018","journal-title":"Cancer Res."},{"key":"10.1016\/j.tranon.2025.102555_bib0073","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1038\/leu.2017.226","article-title":"Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity","volume":"32","author":"Liu","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.tranon.2025.102555_bib0074","doi-asserted-by":"crossref","first-page":"5512","DOI":"10.1158\/1538-7445.AM2022-5512","article-title":"CBLB, CISH and CD70 multiplexed gene knockout with CRISPR\/Cas9 enhances cytotoxicity of CD70-CAR NK cells and provides greater resistance to TGF-\u03b2 for cancer immunotherapy","volume":"82","author":"Guo","year":"2022","journal-title":"Cancer Res."},{"key":"10.1016\/j.tranon.2025.102555_bib0075","article-title":"CD70-targeted iPSC-derived CAR-NK cells display potent function against tumors and alloreactive T cells","volume":"6","author":"Wang","year":"2025","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.tranon.2025.102555_bib0076","doi-asserted-by":"crossref","first-page":"e123","DOI":"10.1016\/j.bbmt.2018.12.756","article-title":"Cytokine release syndrome with chimeric antigen receptor T cell therapy","volume":"25","author":"Frey","year":"2019","journal-title":"Biol. Blood Marrow Transp."},{"key":"10.1016\/j.tranon.2025.102555_bib0077","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.879608","article-title":"Immune effector cell associated neurotoxicity syndrome in chimeric antigen receptor-T cell therapy","volume":"13","author":"Sterner","year":"2022","journal-title":"Front. Immunol."}],"container-title":["Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936523325002864?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936523325002864?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T16:14:35Z","timestamp":1773159275000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1936523325002864"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":77,"alternative-id":["S1936523325002864"],"URL":"https:\/\/doi.org\/10.1016\/j.tranon.2025.102555","relation":{},"ISSN":["1936-5233"],"issn-type":[{"value":"1936-5233","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CD70-targeted CAR-T\/NK therapy: Rationale, advances, and future directions","name":"articletitle","label":"Article Title"},{"value":"Translational Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tranon.2025.102555","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102555"}}